These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 26446169)

  • 1. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
    Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
    Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
    Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
    Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis.
    Albrecht I; Kopfstein L; Strittmatter K; Schomber T; Falkevall A; Hagberg CE; Lorentz P; Jeltsch M; Alitalo K; Eriksson U; Christofori G; Pietras K
    PLoS One; 2010 Nov; 5(11):e14109. PubMed ID: 21124841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling.
    Eleftheriou NM; Sjölund J; Bocci M; Cortez E; Lee SJ; Cunha SI; Pietras K
    Oncotarget; 2016 Dec; 7(51):84314-84325. PubMed ID: 27741515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.
    Yamauchi Y; Kodama Y; Shiokawa M; Kakiuchi N; Marui S; Kuwada T; Sogabe Y; Tomono T; Mima A; Morita T; Matsumori T; Ueda T; Tsuda M; Nishikawa Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Masuda A; Tatsuoka H; Yabe D; Minamiguchi S; Masui T; Inagaki N; Uemoto S; Chiba T; Seno H
    Cancer Res; 2020 Sep; 80(17):3620-3630. PubMed ID: 32591410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.
    Wu Y; Tedesco L; Lucia K; Schlitter AM; Garcia JM; Esposito I; Auernhammer CJ; Theodoropoulou M; Arzt E; Renner U; Stalla GK
    Oncotarget; 2016 Sep; 7(36):57878-57893. PubMed ID: 27506944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A set of microRNAs coordinately controls tumorigenesis, invasion, and metastasis.
    Michael IP; Saghafinia S; Hanahan D
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24184-24195. PubMed ID: 31704767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors.
    Tatura M; Schmidt H; Haijat M; Stark M; Rinke A; Diels R; Lawlor RT; Scarpa A; Schrader J; Hackert T; Schimmack S; Gress TM; Buchholz M
    Neuroendocrinology; 2020; 110(1-2):23-34. PubMed ID: 31018208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.
    Young K; Lawlor RT; Ragulan C; Patil Y; Mafficini A; Bersani S; Antonello D; Mansfield D; Cingarlini S; Landoni L; Pea A; Luchini C; Piredda L; Kannan N; Nyamundanda G; Morganstein D; Chau I; Wiedenmann B; Milella M; Melcher A; Cunningham D; Starling N; Scarpa A; Sadanandam A
    Gut; 2021 Oct; 70(10):1904-1913. PubMed ID: 32883872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.
    How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J
    Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.
    Fielitz K; Althoff K; De Preter K; Nonnekens J; Ohli J; Elges S; Hartmann W; Klöppel G; Knösel T; Schulte M; Klein-Hitpass L; Beisser D; Reis H; Eyking A; Cario E; Schulte JH; Schramm A; Schüller U
    Oncotarget; 2016 Nov; 7(46):74415-74426. PubMed ID: 27769070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy.
    Estrella JS; Ma LT; Milton DR; Yao JC; Wang H; Rashid A; Broaddus RR
    Pancreas; 2014 Oct; 43(7):996-1002. PubMed ID: 25058880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression.
    Saghafinia S; Homicsko K; Di Domenico A; Wullschleger S; Perren A; Marinoni I; Ciriello G; Michael IP; Hanahan D
    Cancer Discov; 2021 Oct; 11(10):2638-2657. PubMed ID: 33910926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant Insulinoma Is Largely Derived From Nonfunctioning Pancreatic Neuroendocrine Tumors: A Contemporary View.
    Yu R
    Pancreas; 2020 Jul; 49(6):733-736. PubMed ID: 32590616
    [No Abstract]   [Full Text] [Related]  

  • 18. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.
    Yang KC; Kalloger SE; Aird JJ; Lee MKC; Rushton C; Mungall KL; Mungall AJ; Gao D; Chow C; Xu J; Karasinska JM; Colborne S; Jones SJM; Schrader J; Morin RD; Loree JM; Marra MA; Renouf DJ; Morin GB; Schaeffer DF; Gorski SM
    Cell Rep; 2021 Oct; 37(2):109817. PubMed ID: 34644566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
    Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
    PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.
    Pal B; Chen Y; Bert A; Hu Y; Sheridan JM; Beck T; Shi W; Satterley K; Jamieson P; Goodall GJ; Lindeman GJ; Smyth GK; Visvader JE
    Breast Cancer Res; 2015 Jun; 17(1):85. PubMed ID: 26080807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.